Boehringer Ingelheim inks 'Singapore's largest biotech deal,' promising $1B each for a suite of anti-fibrotic IL-11 drugs
The deeper Boehringer Ingelheim looks into Asian biotech, the more gems it seems to find. Having picked up new fibrotic diseases drugs left and right …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
